A U.S. judge denies injunction, Novo Nordisk (NVO.US) loses first battle in bid to block Eli Lilly (LLY.US) weight-loss drug advertising

Zhitong Finance APP has learned that on Monday, a U.S. judge rejected Novo Nordisk's (NVO.US) request to prohibit Eli Lilly (LLY.US) from continuing to run advertisements for weight-loss drugs. The Danish pharmaceutical company argued that the advertisements were false and misleading, and the market involved in the advertisements has annual sales of tens of billions of dollars.